ATE328901T1 - Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins - Google Patents

Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins

Info

Publication number
ATE328901T1
ATE328901T1 AT99967832T AT99967832T ATE328901T1 AT E328901 T1 ATE328901 T1 AT E328901T1 AT 99967832 T AT99967832 T AT 99967832T AT 99967832 T AT99967832 T AT 99967832T AT E328901 T1 ATE328901 T1 AT E328901T1
Authority
AT
Austria
Prior art keywords
multiple sclerosis
treatment
peptide analogues
myelin protein
human basic
Prior art date
Application number
AT99967832T
Other languages
English (en)
Inventor
Amitabh Gaur
Paul Conlon
Nicholas C Ling
Theophil Staehlin
Paul Crowe
Original Assignee
Novartis Ag
Novartis Erfind Verwalt Gmbh
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Erfind Verwalt Gmbh, Neurocrine Biosciences Inc filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE328901T1 publication Critical patent/ATE328901T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99967832T 1998-08-20 1999-08-19 Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins ATE328901T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/137,759 US6251396B1 (en) 1994-11-18 1998-08-20 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

Publications (1)

Publication Number Publication Date
ATE328901T1 true ATE328901T1 (de) 2006-06-15

Family

ID=22478925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967832T ATE328901T1 (de) 1998-08-20 1999-08-19 Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins

Country Status (7)

Country Link
US (1) US6251396B1 (de)
EP (1) EP1105419B1 (de)
AT (1) ATE328901T1 (de)
AU (1) AU6020099A (de)
CA (1) CA2340327A1 (de)
DE (1) DE69931793D1 (de)
WO (1) WO2000011027A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
DK1918298T3 (da) * 2000-08-21 2010-11-29 Apitope Technology Bristol Ltd Peptid
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
WO2011109834A2 (en) 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
EP3620185A1 (de) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injizierbare porenbildende hydrogele für materialbasierte zelltherapien
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (de) 2011-04-27 2018-12-26 President and Fellows of Harvard College Zellfreundliche inverse und opake hydrogele zur zelleinkapselung, zur arzneimittel- und proteinabgabe sowie für funktionelle nanopartikeleinkapselung
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
EP3137105A4 (de) 2014-04-30 2017-12-27 President and Fellows of Harvard College Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
CA2998390A1 (en) 2015-09-28 2017-04-06 East Carolina University Aluminum based adjuvants for tolerogenic vaccination
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3484448B1 (de) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigenpräsentierende zellmimetische gerüste und verfahren zur herstellung und verwendung davon
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
EP4034148A4 (de) 2019-09-23 2025-09-10 Harvard College Biomaterialbasierter antigenfreier impfstoff und verwendung davon

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633881B2 (ja) 1986-06-30 1997-07-23 マサチューセッツ インスティテュート オブ テクノロジー 免疫調節組成物及びそれらの使用
DE3856566T2 (de) 1987-06-24 2004-06-24 Brigham And Women's Hospital, Boston Behandlung von Autoimmun-Erkrankungen durch orale Verabreichung von Autoantigenen
DE69127470T2 (de) 1990-03-02 1998-02-19 Autoimmune Inc Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
US6077509A (en) 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
EP0553291B1 (de) 1990-10-15 2006-03-08 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE189230T1 (de) 1991-05-31 2000-02-15 Connetics Corp T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2053799C (en) 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU3418893A (en) 1991-12-24 1993-07-28 Immune Response Corporation, The Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
IL105153A (en) 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
WO1993021222A1 (en) 1992-04-09 1993-10-28 Autoimmune, Inc. Suppression of t-cell proliferation using peptide fragments of myelin basic protein
JPH08503697A (ja) 1992-09-11 1996-04-23 ワシントン ユニバーシティ Ｔ細胞を寛容化するペプチドおよびその組成物
US5559209A (en) 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
CA2172512A1 (en) 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (de) 1994-11-18 2002-08-22 Neurocrine Biosciences, Inc. Peptidanaloga des menschlichen myelinbasischen proteins mit substitution in position 91 zur behandlung von multipler sklerose
WO1996028470A2 (en) 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
DE69637391T2 (de) 1995-05-02 2008-08-14 Alexion Pharmaceuticals, Inc., Cheshire Modifizierte myelin proteinmoleküle
AU5671196A (en) 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof

Also Published As

Publication number Publication date
EP1105419A1 (de) 2001-06-13
WO2000011027A1 (en) 2000-03-02
AU6020099A (en) 2000-03-14
CA2340327A1 (en) 2000-03-02
US6251396B1 (en) 2001-06-26
EP1105419B1 (de) 2006-06-07
DE69931793D1 (de) 2006-07-20

Similar Documents

Publication Publication Date Title
DE69931793D1 (de) Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
AP2000001888A0 (en) Method for treatment of diabetes using peptides analogues of insulin.
DE69525544D1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
WO1996028470A3 (en) Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
ATE377026T1 (de) Behandlung von fettleibigkeit
DE69129115D1 (de) Neues verfahren zur behandlung von depression
DK384084A (da) Vaeksthormonfrigoerende peptider samt fremgangsmaade til behandling af pattedyr hermed
FR2766191B1 (fr) Peptides anti-microbiens de crustaces
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ES2135398T3 (es) Compuesto y composiciones de inhibicion de la resorcion osea.
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
HUT52117A (en) Process for producing amblyommin and process for producing pharmaceutical compositions comprising such compound as active ingredient
ATE121626T1 (de) Verwendung von 20(r)-22-oxa-vitamin d analoge zur herstellung eines medikaments für die behandlung des altershaut.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE60041266D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ES2178393T3 (es) Utilizacion de analogos del vip en la prevencion y el tratamiento de las lesiones cerebrales en el neonato humano.
ATE283276T1 (de) Deoxyhypusin reagenz und peptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties